| US 7,588,771 B2 | ||
| Microorganisms for therapy | ||
| Aladar A. Szalay, Highland, Calif. (US); Tatyana Timiryasova, Scotrun, Pa. (US); Yong A. Yu, San Diego, Calif. (US); and Qian Zhang, San Diego, Calif. (US) | ||
| Assigned to Genelux Corporation, San Diego, Calif. (US) | ||
| Filed on Sep. 27, 2005, as Appl. No. 11/238,025. | ||
| Application 11/238025 is a continuation of application No. 10/872156, filed on Jun. 18, 2004. | ||
| Claims priority of application No. 03013826 (EP), filed on Jun. 18, 2003; application No. 03018478 (EP), filed on Aug. 14, 2003; and application No. 03024283 (EP), filed on Oct. 22, 2003. | ||
| Prior Publication US 2006/0051370 A1, Mar. 09, 2006 | ||
| Int. Cl. A61K 39/285 (2006.01); A61K 39/385 (2006.01); A61K 39/12 (2006.01); A61K 39/20 (2006.01) | ||
| U.S. Cl. 424—232.1 [424/196.11; 424/199.1; 424/93.1] | 21 Claims |
| 1. A method of treatment of cancer, comprising administering a combination of a pharmaceutical composition, and an anti-cancer
treatment or agent to a subject for treatment of cancer, wherein:
the cancer comprises a solid tumor;
treatment comprises an alleviation, reduction or amelioration of clinical symptoms or diagnostic markers associated with the
tumor;
the pharmaceutical composition comprises a recombinant vaccinia virus whose genome contains a modified thymidine kinase (TK)
gene and a modified hemagglutinin (HA) gene, and an insertion, deletion or mutation in the gene or locus designated F3, wherein:
the vaccinia virus is an LIVP strain;
each of the TK, HA and F3 gene or locus is inactivated; and
the F3 gene or locus occurs on the HindIII-F fragment of the LIVP strain of vaccinia virus between open reading frames F14L
and F15L.
|